Literature DB >> 6985790

Renal allografts retained in situ after failure.

H Silberman, T J Fitzgibbons, J Butler, T V Berne.   

Abstract

Twenty-four renal allografts functioning up to six years from the date of transplantation were retained in situ from four days to five years following return of the patient to hemodialysis. Fifteen of the 24 kidneys were removed for specific indications within four days to ten months. The reasons for allograft nephrectomy included fever, hematuria, graft pain and tenderness, and severe hypertension. Nine patients remained asymptomatic with grafts retained three months to five years (median, two years) following return to hemodialysis. It appears safe to retain nonfunctioning grafts in asymptomatic patients, thereby avoiding an unnecessary operation when failure is due to chronic rejection or recurrent glomerulonephritis. Nevertheless, in many patients complications eventually develop for which the allograft will be removed.

Entities:  

Mesh:

Year:  1980        PMID: 6985790     DOI: 10.1001/archsurg.1980.01380010034006

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  3 in total

1.  Early but not late allograft nephrectomy reduces allosensitization after transplant failure.

Authors:  Alp Sener; Anand K Khakhar; Christopher Y Nguan; Andrew A House; Anthony M Jevnikar; Patrick P Luke
Journal:  Can Urol Assoc J       Date:  2011-03-01       Impact factor: 1.862

2.  Transplant nephrectomy improves survival following a failed renal allograft.

Authors:  Juan Carlos Ayus; Steven G Achinger; Shuko Lee; Mohamed H Sayegh; Alan S Go
Journal:  J Am Soc Nephrol       Date:  2009-10-29       Impact factor: 10.121

Review 3.  Nephrectomy Versus Embolization of Non-Functioning Renal Graft: A Systematic Review with a Proportional Meta-Analysis.

Authors:  Henrique Mochida Takase; Mariana Moraes Contti; Hong Si Nga; Ariane Moyses Bravin; Mariana Farina Valiatti; Regina Paolucci El-Dib; Luis Gustavo Modelli de Andrade
Journal:  Ann Transplant       Date:  2018-03-27       Impact factor: 1.530

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.